Nuvation Bio Inc (NUVB) Stock Price, Quote & News

Company Profile

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against place...

Industry: Biotechnology

Sector: Healthcare

Phone: 332 208 6102

Website: www.nuvationbio.com

Address:

1500 Broadway, Suite 1401, New York, United States

CTL1985 Aug. 13 at 10:58 AM

$GORO 👀👀 $CTM 👀👀 $ONDS 👀👀 $ACIU 👀👀 $NUVB 👀👀

0 · Reply

Bio_Invest101 Aug. 12 at 5:14 PM

$NUVB Now you know where those shares in the June Offering gone to … American Century Companies Inc reports 55.32% increase in ownership of NUVB / Nuvation Bio Inc. On August 12, 2026 - American Century Companies Inc filed a 13F-HR form disclosing ownership of 4,499,643 shares of Nuvation Bio Inc. (US:NUVB) valued at $25,557,972 USD as of June 30, 2026. The entity filed a previous 13F-HR on May 15, 2026 disclosing 2,897,078 shares of Nuvation Bio Inc.. This represents a change in shares of 55.32% during the quarter. The current value of the position is $28,662,726 USD. On August 12, 2026 - Geode Capital Management, Llc filed a 13F-HR form disclosing ownership of 6,244,805 shares of Nuvation Bio Inc. (US:NUVB) valued at $35,470,492 USD as of June 30, 2026. The entity filed a previous 13F-HR on May 15, 2026 disclosing 5,863,654 shares of Nuvation Bio Inc.. This represents a change in shares of 6.50% during the quarter. The current value of the position is $39,779,408 USD.

0 · Reply

3day Aug. 12 at 3:30 PM

$NUVB whats next news/catalyst here besides the huge buys forn institutions

1 · Reply

Belisimo Aug. 12 at 1:19 PM

$NUVB Excellent progress being made with latest trial with safusidenib after vorasidemib is discontinued. Just updated with 5 locations now.

0 · Reply

Bio_Invest101 Aug. 12 at 10:28 AM

$NUVB Latest SI 2 million reduction. Ever wonder what’s the Offering done ? Traders will trade. Daily fluctuations happen in all tickers and sectors. Make your own decision accordingly. BLTA

0 · Reply

Bio_Invest101 Aug. 11 at 11:38 PM

$NUVB Wow !! Algert Global Llc reports 532.78% increase in ownership of NUVB / Nuvation Bio Inc. On August 10, 2026 - Algert Global Llc filed a 13F-HR/A form disclosing ownership of 1,842,078 shares of Nuvation Bio Inc. (US:NUVB) valued at $7,902,515 USD as of March 31, 2026. The entity filed a previous 13F-HR/A on August 10, 2026 disclosing 291,108 shares of Nuvation Bio Inc.. This represents a change in shares of 532.78% during the quarter. The current value of the position is $11,761,668 USD.

0 · Reply

Bio_Invest101 Aug. 11 at 9:53 PM

$NUVB Lots of shenanigans going on without real news

0 · Reply

De12 Aug. 11 at 9:28 PM

$NUVB Druckenmiller probably added to his 4.5 Million Shares!

0 · Reply

De12 Aug. 11 at 9:06 PM

$NUVB $IOVA Squeeeze those Shorts!!

0 · Reply

Bio_Invest101 Aug. 11 at 8:17 PM

$NUVB Brand new buyer On August 11, 2026 - First Trust Advisors Lp filed a 13F-HR form disclosing ownership of 1,302,337 shares of Nuvation Bio Inc. (US:NUVB) valued at $7,397,274 USD as of June 30, 2026. The current value of the position is $8,595,424 USD.

0 · Reply

Nuvation Bio price target raised to $14 from $12 at B. Riley

2026-08-07T12:25:29.000Z - 6 days ago

Nuvation Bio price target raised to $20 from $19 at RBC Capital

Aug 6, 2026, 9:00 AM EDT - 7 days ago

Nuvation Bio Slides: Corporate presentation

Aug 6, 2026, 8:00 AM EDT - 7 days ago

Nuvation Bio Earnings Call Transcript: Q2 2026

Aug 6, 2026, 8:00 AM EDT - 7 days ago

Nuvation Bio Quarterly report: Q2 2026

Aug 6, 2026, 8:00 AM EDT - 7 days ago

Nuvation Bio Earnings release: Q2 2026

2026-08-06T11:45:31.000Z - 7 days ago

Nuvation Bio reports Q2 EPS (18c), consensus (12c)

Aug 6, 2026, 7:30 AM EDT - 7 days ago

Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

Aug 4, 2026, 8:00 AM EDT - 9 days ago

Nuvation Bio to Present New Subgroup Analyses of Pivotal Data for IBTROZI® (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses

2026-07-27T12:30:29.000Z - 17 days ago

Nuvation Bio price target raised to $21 from $17 at H.C. Wainwright

Jul 22, 2026, 4:05 PM EDT - 21 days ago

Nuvation Bio to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026

2026-07-20T15:05:17.000Z - 23 days ago

RBC looks for Nuvation shares to appreciate as safusidenib data builds

Jul 20, 2026, 9:00 AM EDT - 24 days ago

Nuvation Bio Slides: Corporate presentation

2026-07-20T12:05:16.000Z - 24 days ago

Nuvation Bio announces data from the Phase 2 J201 study

Jul 20, 2026, 8:00 AM EDT - 24 days ago

Nuvation Bio Announces Positive Updated Phase 2 Data and Expansion of Safusidenib Clinical Program with Two New Studies to Explore Broad Spectrum of IDH1-Mutant Glioma

2026-07-09T21:29:02.000Z - 4 weeks ago

3 Under-$10 Stocks with Strong Upside to Watch This Week, According to Analysts

ABCL SERV UBER

2026-07-07T11:35:44.000Z - 5 weeks ago

Nuvation Bio price target lowered to $19 from $20 at RBC Capital

Jul 6, 2026, 5:09 PM EDT - 5 weeks ago

Nuvation Bio Inc. Announces Full Exercise of Greenshoe Option in $287.5 Million Convertible Senior Notes Offering

2026-06-29T12:05:27.000Z - 6 weeks ago

Nuvation Bio announces MHRA in UK approves MAA for taletrectinib

Jun 29, 2026, 8:00 AM EDT - 6 weeks ago

Nuvation Bio Announces Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated in the United Kingdom

2026-06-26T11:20:42.000Z - 6 weeks ago

Nuvation Bio prices upsized offering of $250M of convertible senior notes

Jun 25, 2026, 11:58 PM EDT - 6 weeks ago

Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes

2026-06-25T14:05:38.000Z - 6 weeks ago

Nuvation Bio falls -10.1%

2026-06-25T11:10:33.000Z - 7 weeks ago

Nuvation Bio files to sell $200M of Convertible Senior Notes due 2032

Jun 25, 2026, 7:00 AM EDT - 7 weeks ago

Nuvation Bio Announces Proposed Convertible Senior Notes Offering

Jun 15, 2026, 7:00 AM EDT - 2 months ago

Nuvation Bio Slides: Corporate presentation

Jun 3, 2026, 9:55 AM EDT - 2 months ago

Nuvation Bio Transcript: Jefferies Global Healthcare Conference 2026

May 27, 2026, 4:05 PM EDT - 2 months ago

Nuvation Bio to Present at the Jefferies Global Healthcare Conference

2026-05-27T14:37:32.000Z - 2 months ago

Nuvation Bio’s Ibtrozi shows improved quality of life in NSCLC trial

May 27, 2026, 8:00 AM EDT - 2 months ago

Nuvation Bio to Present New Quality-of-Life Data for IBTROZI® (Taletrectinib) in Patients with ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2026 Annual Meeting

May 26, 2026, 12:00 PM EDT - 2 months ago

Nuvation Bio Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA

May 21, 2026, 11:00 AM EDT - 2 months ago

Nuvation Bio Transcript: AGM 2026

May 20, 2026, 9:00 AM EDT - 3 months ago

Nuvation Bio Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 19, 2026, 1:30 PM EDT - 3 months ago

Nuvation Bio Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

2026-05-13T20:41:35.000Z - 3 months ago

Nuvation Bio collaborating with Thermo Fisher to manufacture Ibtrozi in NSCLC

TMO

May 13, 2026, 4:05 PM EDT - 3 months ago

Nuvation Bio to Collaborate with Thermo Fisher Scientific for U.S.-Based Manufacturing of IBTROZI® for ROS1-Positive Non-Small Cell Lung Cancer

May 13, 2026, 11:00 AM EDT - 3 months ago

Nuvation Bio Transcript: Bank of America Global Healthcare Conference 2026

2026-05-07T06:20:14.000Z - 3 months ago

Nuvation Bio: FDA accepts sNDA with updated data for IBTROZI

May 6, 2026, 8:00 AM EDT - 3 months ago

Nuvation Bio Announces FDA Acceptance of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in Advanced ROS1-Positive Non-Small Cell Lung Cancer

May 5, 2026, 4:05 PM EDT - 3 months ago

Nuvation Bio to Participate in Upcoming Investor Conferences

May 4, 2026, 4:30 PM EDT - 3 months ago

Nuvation Bio Earnings Call Transcript: Q1 2026

May 4, 2026, 4:30 PM EDT - 3 months ago

Nuvation Bio Quarterly report: Q1 2026

May 4, 2026, 4:30 PM EDT - 3 months ago

Nuvation Bio Earnings release: Q1 2026

2026-05-04T20:17:35.000Z - 3 months ago

Nuvation Bio reports Q1 EPS 1c, consensus 5c

May 4, 2026, 4:10 PM EDT - 3 months ago

Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update

May 4, 2026, 4:00 PM EDT - 3 months ago

Nuvation Bio Slides: Investor presentation

Apr 27, 2026, 8:00 AM EDT - 3 months ago

Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI®) as Recommended Option to Clinical Practice Guidelines in Oncology for Central Nervous System Cancers

2026-04-21T22:05:15.000Z - 4 months ago

Nuvation Bio reports results from TRUST-I and TRUST-II trials for IBTROZI

Apr 21, 2026, 6:00 PM EDT - 4 months ago

Nuvation Bio Announces IBTROZI® (Taletrectinib) Showed Highly Durable Responses in Longer-Term Follow-up Data from Pivotal Studies Presented at AACR 2026

Apr 21, 2026, 8:00 AM EDT - 4 months ago

Nuvation Bio Proxy statement: Proxy filing

Apr 21, 2026, 7:00 AM EDT - 4 months ago

Nuvation Bio Slides: Corporate presentation

Apr 20, 2026, 4:05 PM EDT - 4 months ago

Nuvation Bio to Report First Quarter 2026 Financial Results and Provide Business Update on May 4, 2026

Apr 10, 2026, 8:00 AM EDT - 4 months ago

Nuvation Bio Proxy statement: Proxy filing

2026-04-01T12:16:16.000Z - 4 months ago

Nuvation Bio amends license agreement for safusidenib with Daiichi Sankyo

Apr 1, 2026, 8:00 AM EDT - 4 months ago

Nuvation Bio Announces Acquisition of Japan Rights to Safusidenib from Daiichi Sankyo

2026-03-26T20:10:15.000Z - 4 months ago

Nuvation Bio and Eisai’s MAA for taletrectinib in NSLC accepted in Europe

Mar 26, 2026, 4:05 PM EDT - 4 months ago

Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency

Mar 17, 2026, 4:35 PM EDT - 5 months ago

Nuvation Bio to Present Pivotal IBTROZI® (Taletrectinib) Data in TKI-Naïve and TKI-Pretreated Patients with Advanced ROS1-Positive Non-Small Cell Lung Cancer at AACR 2026

Mar 11, 2026, 8:25 AM EDT - 5 months ago

Nuvation Bio Transcript: The Citizens Life Sciences Conference 2026

Mar 4, 2026, 10:30 AM EST - 5 months ago

Nuvation Bio Transcript: TD Cowen 46th Annual Health Care Conference

Mar 4, 2026, 8:30 AM EST - 5 months ago

Nuvation Bio Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Mar 2, 2026, 4:30 PM EST - 5 months ago

Nuvation Bio Earnings Call Transcript: Q4 2025

Mar 2, 2026, 4:30 PM EST - 5 months ago

Nuvation Bio Annual report: Q4 2025

Mar 2, 2026, 4:30 PM EST - 5 months ago

Nuvation Bio Earnings release: Q4 2025

Mar 2, 2026, 4:05 PM EST - 5 months ago

Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Mar 2, 2026, 7:00 AM EST - 5 months ago

Nuvation Bio Slides: Corporate presentation

Feb 17, 2026, 4:05 PM EST - 6 months ago

Nuvation Bio to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 2, 2026

Feb 9, 2026, 8:00 AM EST - 6 months ago

Nuvation Bio Announces Pivotal Global Phase 3 SIGMA Trial (G203) for Safusidenib in IDH1-Mutant Glioma

Jan 22, 2026, 10:26 AM EST - 7 months ago

These 20 stocks are strong choices for momentum investors

BE CELC COGT FBYD FRGE INBX KOD

Jan 13, 2026, 6:45 PM EST - 7 months ago

Nuvation Bio Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 8:00 AM EST - 7 months ago

Nuvation Bio Reports Preliminary Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook Ahead of 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 7:30 AM EST - 7 months ago

Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan

Jan 12, 2026, 7:00 AM EST - 7 months ago

Nuvation Bio Slides: Corporate presentation

Jan 6, 2026, 4:05 PM EST - 7 months ago

Nuvation Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 6, 2025, 10:40 PM EST - 8 months ago

Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug List

Dec 3, 2025, 9:00 AM EST - 9 months ago

Nuvation Bio Transcript: Citi Annual Global Healthcare Conference 2025

Dec 3, 2025, 8:00 AM EST - 9 months ago

Nuvation Bio Announces Publication of Positive Phase 2 Study Results for Safusidenib for the Treatment of Grade 2 IDH1-Mutant Glioma in Neuro-Oncology

Dec 2, 2025, 9:35 AM EST - 9 months ago

Nuvation Bio Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 1, 2025, 7:00 AM EST - 9 months ago

Nuvation Bio Slides: Corporate Presentation

Nov 19, 2025, 10:00 AM EST - 9 months ago

Nuvation Bio Transcript: Jefferies London Healthcare Conference 2025

Nov 3, 2025, 4:30 PM EST - 10 months ago

Nuvation Bio Earnings Call Transcript: Q3 2025

Nov 3, 2025, 4:30 PM EST - 10 months ago

Nuvation Bio Quarterly report: Q3 2025

Nov 3, 2025, 4:30 PM EST - 10 months ago

Nuvation Bio Earnings release: Q3 2025

Nov 3, 2025, 4:05 PM EST - 10 months ago

Nuvation Bio Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 2, 2025, 12:00 AM EDT - 10 months ago

Nuvation Bio Slides: Corporate Presentation

Oct 23, 2025, 7:30 AM EDT - 10 months ago

Nuvation Bio Enrolls First Patient in Global, Randomized Study of Safusidenib for Maintenance Treatment of High-Grade IDH1-Mutant Glioma

Oct 20, 2025, 4:05 PM EDT - 10 months ago

Nuvation Bio to Report Third Quarter 2025 Financial Results and Provide Business Update on November 3, 2025

Sep 30, 2025, 7:30 AM EDT - 11 months ago

Nuvation Bio Enrolls First Patient in TRUST-IV Phase 3 Study of IBTROZI™ (taletrectinib) for the Adjuvant Treatment of ROS1-Positive Early-Stage Non-Small Cell Lung Cancer

Sep 19, 2025, 7:30 AM EDT - 11 months ago

Nuvation Bio Receives Approval from Japan's Ministry of Health, Labour and Welfare for IBTROZITM for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer

Sep 9, 2025, 11:30 AM EDT - 1 year ago

Nuvation Bio Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 7, 2025, 6:00 AM EDT - 1 year ago

Nuvation Bio Announces New Data from Pivotal Clinical Studies of IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at 2025 World Conference on Lung Cancer

Sep 4, 2025, 2:10 PM EDT - 1 year ago

Nuvation Bio Transcript: Cantor Global Healthcare Conference 2025

Aug 7, 2025, 8:00 AM EDT - 1 year ago

Nuvation Bio Earnings Call Transcript: Q2 2025

Aug 7, 2025, 8:00 AM EDT - 1 year ago

Nuvation Bio Quarterly report: Q2 2025

Aug 7, 2025, 8:00 AM EDT - 1 year ago

Nuvation Bio Earnings release: Q2 2025

Aug 7, 2025, 7:30 AM EDT - 1 year ago

Nuvation Bio Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 6, 2025, 6:00 PM EDT - 1 year ago

Nuvation Bio Slides: Corporate Presentation

Aug 5, 2025, 8:00 AM EDT - 1 year ago

Nuvation Bio To Present New Data on IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses

Jul 24, 2025, 4:05 PM EDT - 1 year ago

Nuvation Bio to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025

Jun 24, 2025, 7:00 AM EDT - 1 year ago

Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI™) as Preferred Option to Clinical Practice Guidelines in Oncology for Advanced ROS1+ Non-Small Cell Lung Cancers

Jun 16, 2025, 7:30 AM EDT - 1 year ago

Onco360 Has Been Selected as a National Specialty Pharmacy Partner for IBTROZI™ (taletrectinib), Manufactured by Nuvation Bio Inc.

Jun 12, 2025, 7:30 AM EDT - 1 year ago

Nuvation Bio Transcript: FDA Announcement

Jun 12, 2025, 7:30 AM EDT - 1 year ago

Nuvation Bio Press release: FDA Announcement

Jun 12, 2025, 7:30 AM EDT - 1 year ago

Nuvation Bio Slides: FDA Announcement

Jun 11, 2025, 1:45 PM EDT - 1 year ago

US FDA approves Nuvation Bio's lung cancer therapy

Jun 11, 2025, 1:20 PM EDT - 1 year ago

U.S. Food and Drug Administration Approves Nuvation Bio's IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer

May 28, 2025, 3:30 PM EDT - 1 year ago

Nuvation Bio Transcript: TD Cowen's 6th Annual Oncology Innovation Summit

May 21, 2025, 4:05 PM EDT - 1 year ago

Nuvation Bio To Present New Data from Pivotal Clinical Studies of Taletrectinib in Advanced ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2025 Annual Meeting

May 21, 2025, 1:35 PM EDT - 1 year ago

Nuvation Bio Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 20, 2025, 3:00 PM EDT - 1 year ago

Nuvation Bio Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 13, 2025, 4:05 PM EDT - 1 year ago

Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Entrectinib at ISPOR 2025

May 8, 2025, 10:00 AM EDT - 1 year ago

Nuvation Bio Transcript: The Citizens JMP Life Sciences Conference 2025

May 7, 2025, 4:30 PM EDT - 1 year ago

Nuvation Bio Earnings Call Transcript: Q1 2025

May 7, 2025, 4:30 PM EDT - 1 year ago

Nuvation Bio Quarterly report: Q1 2025

May 7, 2025, 4:30 PM EDT - 1 year ago

Nuvation Bio Earnings release: Q1 2025

May 7, 2025, 4:05 PM EDT - 1 year ago

Nuvation Bio Reports First Quarter 2025 Financial Results and Provides Business Update

May 1, 2025, 4:05 PM EDT - 1 year ago

Nuvation Bio to Present at The Citizens Life Sciences Conference

CTL1985 Aug. 13 at 10:58 AM

$GORO 👀👀 $CTM 👀👀 $ONDS 👀👀 $ACIU 👀👀 $NUVB 👀👀

0 · Reply

Bio_Invest101 Aug. 12 at 5:14 PM

0 · Reply

3day Aug. 12 at 3:30 PM

$NUVB whats next news/catalyst here besides the huge buys forn institutions

1 · Reply

Belisimo Aug. 12 at 1:19 PM

$NUVB Excellent progress being made with latest trial with safusidenib after vorasidemib is discontinued. Just updated with 5 locations now.

0 · Reply

Bio_Invest101 Aug. 12 at 10:28 AM

$NUVB Latest SI 2 million reduction. Ever wonder what’s the Offering done ? Traders will trade. Daily fluctuations happen in all tickers and sectors. Make your own decision accordingly. BLTA

0 · Reply

Bio_Invest101 Aug. 11 at 11:38 PM

0 · Reply

Bio_Invest101 Aug. 11 at 9:53 PM

$NUVB Lots of shenanigans going on without real news

0 · Reply

De12 Aug. 11 at 9:28 PM

$NUVB Druckenmiller probably added to his 4.5 Million Shares!

0 · Reply

De12 Aug. 11 at 9:06 PM

$NUVB $IOVA Squeeeze those Shorts!!

0 · Reply

Bio_Invest101 Aug. 11 at 8:17 PM

0 · Reply

Shagg85 Aug. 11 at 7:07 PM

$NUVB love the drop of 2% in 10 mins lol In my opinion the only explanation is market makers are preparing for a massive run. I believe it’s in very near future

1 · Reply

JanetBSmellin Aug. 11 at 6:23 PM

$IBRX $NUVB Nice little day to not be behind a desk. As always, f*** cancer, and f*** big pharma. ☀️🏝️😺

4 · Reply

njbugatti Aug. 11 at 5:13 PM

$NUVB https://nuvationbio.com/wp-content/uploads/2026/04/ROS1_NSCLC_Testing__Treatment_Brochure.pdf

0 · Reply

JuggernautRaider Aug. 11 at 3:51 PM

Dude you can turns cans into real cash if you know what you’re doing $NUVB $SLS $IMRX $TNXP all winners 💎

0 · Reply

Tomthefirst Aug. 11 at 2:38 PM

$NUVB swing to 7 is coming

0 · Reply

Tomthefirst Aug. 11 at 2:37 PM

$AUTL Anyone with 2 dollars to spare should take a look at $NUVB

1 · Reply

Bio_Invest101 Aug. 11 at 2:23 PM

$NUVB More to come Nuveen, LLC reports 110.77% increase in ownership of NUVB / Nuvation Bio Inc. On August 11, 2026 - Nuveen, LLC filed a 13F-HR form disclosing ownership of 1,083,628 shares of Nuvation Bio Inc. (US:NUVB) valued at $6,155,007 USD as of June 30, 2026. The entity filed a previous 13F-HR on April 30, 2026 disclosing 514,117 shares of Nuvation Bio Inc.. This represents a change in shares of 110.77% during the quarter. The current value of the position is $7,151,945 USD.

0 · Reply

Shagg85 Aug. 11 at 2:03 PM

$NUVB when are these Fu*kin market makers going let this go? They won’t even let it follow the market up.

1 · Reply

Incognito_21 Aug. 10 at 9:29 PM

$NUVB quite a day let’s see some moves this week

0 · Reply

ejz92 Aug. 10 at 8:05 PM

$NUVB Another strong finish

0 · Reply

Bio_Invest101 Aug. 9 at 9:36 PM

$NUVB After listening to the ER call again, I agree the RNA testing in ROS1 will help Ibtrozi to build up strong patients base and become the 1L and SoC drug of choice contender quickly more important than anything else when the sales team working on the oncologist and their patients in community health centers. Not sure if Dr Hung could partner or invest in such RNA testing services and I think the costs could be quite high. FLASCO program provides some good quality information from front line oncologists practices https://youtu.be/yOjvzt1K83k?is=80eDLMwInUWPGdpc

1 · Reply

Belisimo Aug. 9 at 1:02 PM

$NUVB Anonx biggest new position back in June 26th filing date

0 · Reply

Market Cap	2.22B
Revenue (ttm)	62.90M
Net Income (ttm)	-204.63M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-325.33%
Debt to Equity Ratio	0.02

Volume	2,592,600
Avg Vol	7,031,228
Day's Range	N/A - N/A
Shares Out	348.20M
Stochastic %K	60%
Beta	1.52
Analysts	Strong Sell
Price Target	$13.33